drugset / Trial / NCT01302964

Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders

NCT01302964

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will determine the effectiveness of mirtazapine in reducing anxiety in children with autistic disorder, Asperger's disorder and Pervasive Developmental Disorder.

Timeline

Start
2010-08
Primary completion
2017-10-10
Completion
2017-10-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Mirtazapine Other / unclassified 45 mg